These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 1619782)
1. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells. Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of effector cell activities in mice bearing syngeneic plasmacytoma X5563 by a biological response modifier, PSK. Matsunaga K; Iijima H; Aota M; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K J Clin Lab Immunol; 1992 Jan; 37(1):21-37. PubMed ID: 1339233 [TBL] [Abstract][Full Text] [Related]
3. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide]. Yang ZB Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654 [TBL] [Abstract][Full Text] [Related]
4. Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, krestin. Hayashida Y; Kurimoto S; Yamamoto N Biochem Biophys Res Commun; 1991 Jan; 174(1):107-14. PubMed ID: 1899189 [TBL] [Abstract][Full Text] [Related]
5. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts. Matsunaga K; Morita I; Iijima H; Endo H; Oguchi Y; Yoshimura M; Fujii T; Yoshikumi C; Nomoto K J Clin Lab Immunol; 1990 Mar; 31(3):127-36. PubMed ID: 1966997 [TBL] [Abstract][Full Text] [Related]
6. [Restoration of depressed immune responses by PSK in C3H/He mice bearing the syngeneic X5563 tumor]. Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K Gan To Kagaku Ryoho; 1986 Dec; 13(12):3453-60. PubMed ID: 3789756 [TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells. Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049 [TBL] [Abstract][Full Text] [Related]
8. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells. Kawase I; Shirasaka T; Ikeda T; Hara H; Tanio Y; Watanabe M; Saito S; Masuno T; Kishimoto S; Yamamura Y Jpn J Cancer Res; 1989 Nov; 80(11):1098-105. PubMed ID: 2481664 [TBL] [Abstract][Full Text] [Related]
9. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells. Saarloos MN; Khoo NK; Lala PK Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293 [TBL] [Abstract][Full Text] [Related]
10. [Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors]. Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K Gan To Kagaku Ryoho; 1986 Dec; 13(12):3461-7. PubMed ID: 3789757 [TBL] [Abstract][Full Text] [Related]
11. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde. Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin TH; Chu TM Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751 [TBL] [Abstract][Full Text] [Related]
13. Protein-bound polysaccharide-K reduces the proportion of regulatory T cells in vitro and in vivo. Aoki R; Iijima H; Kato M; Uchida M; Wada T; Murata M; Ogawa K; Naritaka Y; Yoshimatsu K Oncol Rep; 2014 Jan; 31(1):50-6. PubMed ID: 24190620 [TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK. Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y Oncology; 1994; 51(3):296-302. PubMed ID: 8196915 [TBL] [Abstract][Full Text] [Related]
16. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity. Kawase I; Komuta K; Shirasaka T; Hara H; Tanio Y; Watanabe M; Saito S; Ikeda T; Masuno T; Kishimoto S Jpn J Cancer Res; 1989 Nov; 80(11):1089-97. PubMed ID: 2514171 [TBL] [Abstract][Full Text] [Related]
17. [Restoration of immunologic responsiveness by PSK in tumor-bearing animals]. Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K Gan To Kagaku Ryoho; 1986 Dec; 13(12):3468-75. PubMed ID: 3789758 [TBL] [Abstract][Full Text] [Related]
18. [Effect of PSK on Th1/Th2 balance in tumor-bearing mice]. Wada T; Iijima H; Sekine F; Kato M; Tsugane M; Oguchi Y; Matsunaga K; Ando T; Nomoto K Gan To Kagaku Ryoho; 2003 Oct; 30(11):1798-801. PubMed ID: 14619523 [TBL] [Abstract][Full Text] [Related]
19. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors. Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605 [TBL] [Abstract][Full Text] [Related]
20. Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK. Suo J; Tanaka N; Hizuta A; Yunoki S; Orita K Acta Med Okayama; 1994 Oct; 48(5):237-42. PubMed ID: 7863794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]